Csl Ltd - CSLLY STOCK NEWS

CSL Seqirus, a business of CSL, announced a real-world evidence study showing that a cell-based quadrivalent influenza vaccine was more effective than egg-based vaccines in preventing test-confirmed influenza over three seasons. The study revealed a relative vaccine effectiveness of at least 10% higher for the cell-based vaccine across three flu seasons.

CSL Vifor and Travere Therapeutics receive conditional marketing authorization from the European Commission for FILSPARI (sparsentan) for the treatment of IgA Nephropathy, marking a significant advancement in non-immunosuppressive therapy for this rare kidney disease.

CSL Vifor receives Health Canada authorization for Ferinject to treat iron deficiency anemia and heart failure, expanding treatment options for patients.

CSL Seqirus is prepared to deliver its influenza vaccine portfolio for the 2024/25 U.S. season following FDA recommendations. The company will transition to trivalent formulations, excluding the B/Yamagata strain. CSL Seqirus received FDA approval for its trivalent vaccines and aims to improve vaccine confidence and immunization rates globally.

CSL Limited reports strong financial performance with revenue of $8.05 billion, a 11% increase. Net profit after tax is $1.90 billion, up 20% on a constant currency basis. CSL Behring's portfolio growth, especially in immunoglobulins, drove the positive results. The company reaffirms its guidance for FY24 with anticipated NPATA of $2.9 billion to $3.0 billion at constant currency.

CSL (ASX:CSL; USOTC:CSLLY) announces Phase 3 AEGIS-II trial results for CSL112, which did not meet primary efficacy endpoint of MACE reduction at 90 days. No immediate regulatory filing planned. Ongoing analysis to be presented at ACC Scientific Sessions in April 2024.

A study conducted by Meiji Seika Pharma in Japan compared ARCT-154, the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine, with a conventional mRNA COVID-19 vaccine. The data showed that ARCT-154 induces a longer immune response and has an advantage in antibody persistence compared to the conventional vaccine. The study demonstrated the continuous advantage of sa-mRNA over conventional mRNA vaccine in terms of the duration of the immune response. The sa-mRNA technology has the potential to provide significant advancements over conventional mRNA vaccines including prolonged protection at lower doses.

CSL and Arcturus Therapeutics announce positive results of a Phase 3 study evaluating a booster dose of ARCT-154, the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine, compared to a conventional mRNA COVID-19 vaccine. The study conducted in Japan demonstrates Immunological Non-Inferiority to Wuhan Strain and Superior Immunogenicity to Omicron BA.4/5 Variant. The new analysis at 6 months post-vaccination shows that ARCT-154 induces a longer immune response compared to Comirnaty for both the original Wuhan strain and Omicron BA.4/5 variant, and an advantage in antibody persistence. The results follow the approval of the world's first sa-mRNA COVID-19 vaccine for adults by Japan Ministry of Health, Labor and Welfare in November 2023.

CSL Behring's survey results show that patients with CIDP prioritize convenience and flexibility in treatment, with a majority interested in exploring more convenient treatment options and administering treatment at home. However, less than half of the patients discuss potential new treatment options or switching treatments with a physician. The survey also revealed that patients wish their physicians better understood their priorities in CIDP treatment, including efficacy, minimal side effects, condition maintenance, at-home administration, and flexible dosing options.